Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000731766
$424.98
+1.91% · delayed ~15 min
Last price from Oct 22, 2026
$385.03B market value
From UNITEDHEALTH GROUP INC's FY2025 10-K, filed Mar 2, 2026 · read the filing
UNITEDHEALTH sells insurance. It took in $447.57B last year, which makes it one of the largest companies in the world. Of every dollar it sells, about 3 cents is left as profit.
The financial picture is mixed, with profitability, growth and debt needing attention.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From UNITEDHEALTH GROUP INC's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$32.29B → $18.96B
Profit
$14.40B → $12.06B
Operating margin
8.1% → 4.2%
Free cash flow
$20.70B → $16.07B
Measured against FY2024, from the 10-K filed Mar 2, 2026
Deteriorated: -41.3%
$32.29B to $18.96BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -16.3%
$14.40B to $12.06BSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
UNH rose 1.91% on the latest quote. The average Financials company tracked here moved +1.10%, and the S&P 500 −1.04%. That is 0.8 points above its sector and 3.0 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 33 analysts covering this company, as of . Their views, not this site's.
Of 33 analysts publishing on this company, 8 say strong buy, 18 say buy and 7 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 3 cents of every dollar of sales as profit, earning $12.06B last year.
Slowly. Sales grew 11.8% last year.
For every $1 it owes, it owns $1.49 in assets. Banks and insurers always carry high debt — that is how lending works — so this is normal for the industry and not comparable with other sectors.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 66 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 40% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $12.06B and generated $19.70B of cash from operations.
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Mar 2, 2026Filing for FY2025 | FY202410-K · Feb 27, 2025Filing for FY2024 | FY202310-K · Feb 28, 2024Filing for FY2023 | FY202210-K · Feb 24, 2023Filing for FY2022 | FY202110-K · Feb 24, 2023Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $447.57B | $400.28B | $371.62B | $324.16B | $287.60B | +11.8% |
| Cost of revenue | $50.66B | $46.69B | $38.77B | $33.70B | $31.03B | +8.5% |
| Gross profit | $396.91B† | $353.58B† | $332.85B† | $290.46B† | $256.56B† | +12.3% |
| Gross marginGross profit ÷ revenueWhat is this? | 88.7% | 88.3% | 89.6% | 89.6% | 89.2% | +0.3 pts |
| Selling, general and administrative | $59.59B | $53.01B | $54.63B | $47.78B | $42.58B | +12.4% |
| Operating income | $18.96B | $32.29B | $32.36B | $28.43B | $23.97B | −41.3% |
| Operating marginOperating income ÷ revenueWhat is this? | 4.2% | 8.1% | 8.7% | 8.8% | 8.3% | −3.8 pts |
| Interest expense | $4.00B | $3.91B | $3.25B | $2.09B | $1.66B | +2.5% |
| Income before tax | $14.70B | $20.07B | $29.11B | $26.34B | $22.31B | −26.8% |
| Net income | $12.06B | $14.40B | $22.38B | $20.12B | $17.29B | −16.3% |
| Net marginNet income ÷ revenueWhat is this? | 2.7% | 3.6% | 6.0% | 6.2% | 6.0% | −0.9 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $13.31 | $15.74 | $24.22 | $21.54 | $18.37 | −15.5% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH GROUP INC · this page | 6.0/10 | 7/9 | 11.8% | 2.7% | 31.94x | 2.08x |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Was granted or awarded shares — 257 shares
Holds 2,668 shares after this filing.
Was granted or awarded shares — 262 shares
Holds 11,205 shares after this filing.
Was granted or awarded shares — 155 shares
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Published results
Read the filingMade a Regulation FD disclosure
Read the filingWrite down why you are following UNITEDHEALTH GROUP INC, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 10 subsidiaries named in its 10-K, incorporated across 4 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from UNH's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Mar 2, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 6.0 | 7/9 | 10-K, filed Mar 2, 2026 |
| FY2024 | 6.0 | 5/9 | 10-K, filed Feb 27, 2025 |
| FY2023 | 6.0 | 8/9 | 10-K, filed Feb 28, 2024 |
| FY2022 | 6.0 | 6/9 | 10-K, filed Feb 24, 2023 |
| FY2021 | 6.0 | 8/9 | 10-K, filed Feb 15, 2022 |
| FY2020 | 6.0 | 7/9 | 10-K, filed Mar 1, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
7 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −3.8 pts
8.1% to 4.2%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: -22.4%
$20.70B to $16.07BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -15.5%
$15.74 to $13.31Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +11.8%
$400.28B to $447.57BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +12.3%
$353.58B to $396.91BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Changed: +5.1%
$7.53B to $7.92BNotable
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 10, 2026 — read it.
Improved: +55.2%
$5.15B to $7.99BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +61.0%
$3.41B to $5.48BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +61.0%
$3.76 to $6.06Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +2.5 pts
4.6% to 7.1%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +1.8 pts
3.1% to 4.9%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: -5.4%
$73.50B to $69.50BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 10, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: -11.1%
$8.99B to $7.99BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -12.7%
$6.28B to $5.48BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: -12.4%
$6.92 to $6.06Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
6 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 22.0x — investors pay $22.0 for each $1 of trailing profit.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Reported annual figures
| 6.0/10 |
| 6/9 |
| 12.5% |
| 2.8% |
| 17.36x |
| 1.77x |
| HUMHUMANA INC | 6.0/10 | 5/8 | 10.1% | 0.9% | 42.75x | 1.77x |
|---|
| CNCCENTENE CORP | 4.7/10 | 4/9 | 20.0% | -3.8% | — | 2.84x |
|---|
| MOHMOLINA HEALTHCARE, INC. | 6.0/10 | 4/9 | 11.7% | 1.0% | 23.41x | 2.83x |
|---|
| Median of peers | 6.0/10 | — | 12.1% | 1.0% | 23.41x | 2.30x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Holds 4,077 shares after this filing.
Was granted or awarded shares — 103 shares
Holds 4,180 shares after this filing.
Was granted or awarded shares — 240 shares
Holds 2,867 shares after this filing.
Was granted or awarded shares — 257 shares
Holds 921 shares after this filing.
Was granted or awarded shares — 291 shares
Holds 15,810 shares after this filing.
Was granted or awarded shares — 257 shares
Holds 8,180 shares after this filing.
Was granted or awarded shares — 240 shares
Holds 7,902 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 1,169 shares ($455.9K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 500 shares ($205.0K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q2 FY2026
Operating margin +2.5 pts · Operating income +55.2% · Profit +61.0% — against Q2 FY2025
Published results
Read the filingHeld a shareholder vote
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q1 FY2026
Free cash flow +78.8% · Capital spending -15.0% · Cash -8.8% — against Q1 FY2025
Read the filingProxy statement for a shareholder meeting
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingAnnual report for FY2025
Revenue +11.8% · Operating margin −3.8 pts · Operating income -41.3% — against FY2024
Read the filingHad a director or senior officer leave or join
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingAmended its charter or changed its financial year
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +12.2% · Operating margin −4.8 pts · Operating income -50.4% — against Q3 FY2024
Read the filingPublished results
Read the filingSource: Exhibit 21 of the 10-K filed 2026-03-02. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know
Yahoo Finance ·
UnitedHealth's Earnings Jumped 60%. Is the Comeback Stock a Buy, Sell, or Hold?
Yahoo Finance ·
Sector Update: Healthcare Stocks Softer Late Afternoon
Yahoo Finance ·
UnitedHealth (UNH): Does Optum Truly Diversify Its Earnings Risk?
Yahoo Finance ·
Should You Invest in UnitedHealth (UNH) Based on Bullish Wall Street Views?
Yahoo Finance ·
What Elevance Health (ELV) Said on Its Q3 Earnings Call
Yahoo Finance ·
SCHD’s Price May Be Soaring, but Its Dividend Isn’t Keeping Up
Yahoo Finance ·
UnitedHealthcare to Support Northeast Missouri Health Council Efforts to Sustain and Expand Rural Maternal Healthcare
Yahoo Finance ·
UnitedHealth Group (UNH) Will Raise 2027 Medicare Costs For Seniors
Yahoo Finance ·
What Does Progyny's Falling Multiple Really Say?
Yahoo Finance ·
Microsoft and Alphabet opt out of tokenized stocks—the latest blow to an ambitious plan to shake up trading
Yahoo Finance ·
What Could Stop CVS Health Stock Over The Next Six Months?
Yahoo Finance ·
Primary sources and further research